Cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in patients with severe mental illness
DOI:
https://doi.org/10.33393/grhta.2020.2027Keywords:
Budget impact analysis, Cardiometabolic risk, Cost-effectiveness, Lifestyle intervention, Mental health care, Severe mental illnessesAbstract
Methods: Patients (n = 244) were randomized to receive either care-as-usual or a lifestyle intervention in which mental health nurses coached patients in changing their lifestyle by using a web tool. Costs and quality of life were assessed at baseline and at 6 and 12 months. Incremental costs per centimeter waist circumference (WC) lost and per Quality-Adjusted Life Year (QALY) gained were assessed. Budget impact was estimated based on three intervention-uptake scenarios using a societal and a third-party payer perspective.
Results: Costs and reduction in WC were higher in the intervention (n = 114) than in the control (n = 94) group after 12 months, although not statistically significant, resulting in €1,370 per cm WC lost. QALYs did not differ between the groups, resulting in a low probability of the intervention being cost-effective in cost/QALY gained. The budget impact analysis showed that for a reasonable participation of 43%, total costs were around €81 million over 5 years, or on average €16 million annually (societal perspective).
Conclusions: The intervention is not cost-effective at 12 months and the budget impact over 5 years is substantial. Possibly, 12 months was too short to implement the intervention, improve cardiometabolic health, and reduce care costs. Therefore, the incentive for this intervention cannot be found in short-term financial advantages. However, there may be benefits associated with lifestyle interventions in the long term that remain unclear.
Downloads
References
De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77.
Bruins J, Jörg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PLoS One. 2014; 9(12):e112276.
McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull. 2016;42(1):96-124.
Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act. 2011;8(1):28.
Verhaeghe N, De Smedt D, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Cost-effectiveness of health promotion targeting physical activity and healthy eating in mental health care. BMC Public Health. 2014;14(1):856.
Green CA, Yarborough BJH, Leo MC, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172(1):71-81.
Organisation for Economic Co-operation and Development (OECD). http://www.oecd.org. Updated 2017.
Meenan RT, Stumbo SP, Yarborough MT, Leo MC, Yarborough BJH, Green CA. An economic evaluation of a weight loss intervention program for people with serious mental illnesses taking antipsychotic medications. Adm Policy Ment Health. 2016;43(4):604-615.
Looijmans A, Jörg F, Bruggeman R, Schoevers R, Corpeleijn E. Design of the Lifestyle Interventions for severe mentally ill Outpatients in the Netherlands (LION) trial; a cluster randomised controlled study of a multidimensional web tool intervention to improve cardiometabolic health in patients with severe mental illness. BMC Psychiatry. 2017;17(1):107.
Looijmans A, Jörg F, Bruggeman R, Schoevers R, Corpeleijn E. Multimodal lifestyle intervention using a web-based tool to improve cardiometabolic health in patients with serious mental illness: results of a cluster randomized controlled trial (LION). BMC Psychiatry. 2019;19(1):339.
Brazier JE, Roberts JJMc. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851-859.
Kharroubi SA, Brazier JE, Roberts J, O’Hagan A. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ. 2007;26(3):597-612.
McCabe C, Brazier J, Gilks P, et al. Using rank data to estimate health state utility models. J Health Econ. 2006;25(3):418-431.
Nederland DZ. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. 2016.
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17(1):5-14.
Statline from Statistics Netherlands (CBS), July 2016; http://statline.cbs.nl/Statweb/
Delespaul P. Consensus over de definitie van mensen met een ernstige psychische aandoening (EPA) en hun aantal in Nederland. Tijdschrift voor psychiatrie, 2013.
van Alphen A, Ammeraal M, Blanke C, et al. Multidisciplinaire richtlijn schizofrenie. 2012. Versie 2.0. Trimbos instituut.
Boonstra N, Wunderink L, de Wit PHM, Noorthoorn E, Wiersma D. De administratieve incidentie van niet-affectieve psychosen in Friesland en Twente. Tijdschrift voor Psychiatrie. 2008;50(10):637.
Hakkaart-van Roijen L, van der Linden N, Bouwmans C, Kanters T, Tan SS. Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg In opdracht van Zorginstituut Nederland Geactualiseerde versie. 2015.
Nederland Zorginstituut [Dutch Care Institute], July 2016; www.medicijnkosten.nl.
Oostenbrink JB, Rutten F. Cost assessment and price setting of inpatient care in the Netherlands. The DBC case-mix system. Health Care Manag Sci. 2006;9(3):287-294.
IBM Corp., IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. 2013.
Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E‐ratios alongside a clinical trial. Health Econ. 1994;3(5):309-319.
RIVM Cost of Illness database, 2013; www.costofillness.nl.
Heslin M, Patel A, Stahl D, et al. Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion. BMC Psychiatry. 2017;17(1):407.
Holt RI, Hind D, Gossage-Worrall R, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess. 2018;22(65):1.
Green CA, Yarborough BJH, Leo MC, et al. Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications. Obesity. 2015;23(10):1995-2001.
Stiekema AP, Looijmans A, van der Meer L, et al. Effects of a lifestyle intervention on psychosocial well-being of severe mentally ill residential patients: ELIPS, a cluster randomized controlled pragmatic trial. Schizophr Res. 2018;199:407-413.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.
Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2020-06-19
Published 2020-12-14
